Canada - English - Health Canada

pfizer canada ulc - testosterone cypionate - solution - 100mg - testosterone cypionate 100mg - androgens

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - testosterone, quantity: 0.05 g - gel - excipient ingredients: purified water; sodium hydroxide; carbomer 980; ethanol; isopropyl myristate - indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - testosterone propionate, quantity: 30 mg/ml; testosterone phenylpropionate, quantity: 60 mg/ml; testosterone isocaproate, quantity: 60 mg/ml; testosterone decanoate, quantity: 100 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; arachis oil - indicatiosns as at 4 december 1996: androgen replacement therapy for confirmed testosterone deficiency in males.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - testosterone - gel - testosterone 25 mg/dose - testosterone - testosterone - testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - testosterone - gel - testosterone 50 mg/dose - testosterone and estrogen - testosterone and estrogen - testosterone replacement therapy for males hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - testosterone, quantity: 24.3 mg - drug delivery system, transdermal - excipient ingredients: ethanol; sodium hydroxide; glyceryl monooleate; methyl laurate; carbomer copolymer (type b); glycerol; purified water; ethyl acetate; toluene; acrylates/va copolymer - indicated for testosterone replacement therapy for confirmed testosterone deficiency in males.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - testosterone decanoate; testosterone isocaproate; testosterone propionate; testosterone phenylpropionate - parenteral liquid/solution/suspension - testosterone decanoate steroid-anabolic active 20.0 mg/ml; testosterone isocaproate steroid-anabolic active 12.0 mg/ml; testosterone propionate steroid-anabolic active 6.0 mg/ml; testosterone phenylpropionate steroid-anabolic active 12.0 mg/ml - endocrine system - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - anabolic steroid | abortion threat | androgenic properties | bone repair | catabolic complications | convalescence | erythropoietic activity | geriatric therapy | improve appetite | male sexual characterisitics | muscle development | non-virilising anabolic | pathophysiological process | protein and mineral anabolic | skeletal conditions | tissue breakdown | tissue repair | virilising anabolic

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - testosterone enanthate - parenteral liquid/solution/suspension - testosterone enanthate steroid-anabolic active 75.0 mg - endocrine system - sheep wether (castrated male) | castrated male | ovine - external preputial ulceration | sheath rot

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - depo-testosterone injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of depo-testosterone (testosterone cypionate) in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. depo-testosterone injection contains testosterone, a schedule iii controlled substance in the controlled substances act. drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. abuse and misuse of testosterone are seen in male and female adults and adolescents. testosterone, often in combination with other anabolic androgenic steroids (aas), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. there have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. the following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. the following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. the following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate 200 mg in 1 ml - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy) - patients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule iii controlled substance in th